Ardelyx Inc

NASDAQ:ARDX   3:59:32 PM EDT
1.14
-0.06 (-4.62%)
4:14:19 PM EDT: $1.12 -0.02 (-1.32%)
Products, Layoffs, Earnings Announcements

Ardelyx Inc Provides Corporate Update Following Type A Meeting With FDA

Published: 10/13/2021 12:31 GMT
Ardelyx Inc (ARDX) - Ardelyx Provides Corporate Update Following Type a Meeting With FDA.
Ardelyx - Despite Type a Meeting, Co Continues to Await Clarity From FDA on Path Forward for Approval of Tenapanor for Hyperphosphatemia.
Ardelyx - on Oct 12, Began Implementing Restructuring Plan Following Receipt of Complete Response Letter From FDA on July 28, 2021.
Ardelyx - Restructuring Plan is Expected to Be Completed in December 2021.
Ardelyx - Related to Restructuring, Co Estimates It Will Incur Restructuring Charges of About $2.3 Million, to Be Recorded Primarily in Q4 2021.
Ardelyx - Expects Workforce Reduction Will Decrease Its Annual Cash Compensation Costs by About $18.1 Million.
Revenue is expected to be $1.57 Million
Adjusted EPS is expected to be -$0.34

Next Quarter Revenue Guidance is expected to be $0.6 Million
Next Quarter EPS Guidance is expected to be -$0.31

More details on our Analysts Page.